The Lancet Diabetes & Endocrinology最新文献

{"title":"Long-term outcomes and challenges of islet transplantation in type 1 diabetes","authors":"Mikael Chetboun, François Pattou","doi":"10.1016/s2213-8587(25)00003-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00003-8","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"15 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy","authors":"Davide Catarinella, Raffaella Melzi, Alessia Mercalli, Paola Magistretti, Stefano Tentori, Chiara Gremizzi, Vera Paloschi, Francesco De Cobelli, Giuseppe Esposto, Sabrina Costa, Antonio Secchi, Rossana Caldara, Paola Maffi, Rita Nano, Lorenzo Piemonti","doi":"10.1016/s2213-8587(24)00341-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00341-3","url":null,"abstract":"<h3>Background</h3>Islet transplantation has the potential to cure type 1 diabetes by restoring endogenous insulin production. However, its success relies on balancing improved glycaemic control with the risks of immunosuppressive therapy. This study aimed to evaluate long-term outcomes of islet transplantation alone for type 1 diabetes, focusing on the effects of islet mass and immunosuppressive regimens on graft survival and insulin independence, and weighing glycaemic control benefits against the risks of immunosuppressive therapy.<h3>Methods</h3>This cohort study retrospectively analysed individuals aged 18–67 years with type 1 diabetes who received intraportal islet transplantation alone at IRCCS Ospedale San Raffaele, Milan, Italy. Inclusion criteria comprised adults with type 1 diabetes diagnosed before the age of 55 years with severe recurrent hypoglycaemia or glycaemic instability. Major exclusion criteria included a HbA<sub>1c</sub> of more than 12·5%, a BMI of more than 30 kg/m<sup>2</sup>, and insulin requirements exceeding 1·2 IU/kg per day, along with contraindications to immunosuppressive therapy. Participants were recruited from the hospital's islet transplant registry. Follow-up was conducted through regular clinical visits, with data collected retrospectively. Outcomes assessed included patient survival, graft survival, insulin independence, glycaemic control, and adverse events. Data were analysed using an intention-to-treat method, mixed-effects models, Kaplan–Meier estimates, and Cox and logistic regression to identify factors linked to metabolic success and reduced risks.<h3>Findings</h3>79 patients underwent intrahepatic or intraportal islet transplantation alone between Feb 16, 2001, and June 1, 2023, and received a total of 159 islet infusions, with a median total islet mass of 9637 islet equivalents (IEQ) per kg. Complications were infrequent and mostly involved minor bleeding, with only 3% (two of 79) of patients requiring surgical intervention. Glycaemic control improved significantly after infusion, with a reduction of HbA<sub>1c</sub> by –10·04 mmol/mol (–13·63 to –6·46), and a decrease in daily insulin requirements by –13·35 units per day (–17·04 to –9·65). The intention-to-treat analysis showed a median graft survival (fasting C peptide ≥0·3 ng/mL) of 3·9 years (95% CI 1·6 to 6·2) and 44% (35/79) insulin independence for a median of 6 years (95% CI 2·88 to 9·08). Patients receiving more than 10 000 IEQ/kg with BAS, FK506, and Rapa therapy had a median graft survival of 9·7 years (3·1–16·0) and 73% (16 of 22) insulin independence. Kaplan–Meier estimates indicated graft survival rates of 86% at 1 year, 65% at 5 years, 47% at 10 years, 47% at 15 years, and 40% at 20 years. Overall survival was 92% (73 of 79) over a median follow-up of 13·1 years, with a 20-year survival probability of 84%. Adverse events related to immunosuppressive therapy were reported in 44% (35 of 79) of patients, with allosensitisation rates incr","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"11 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is a normal glucose value?","authors":"Viral N Shah, David Kerr","doi":"10.1016/s2213-8587(25)00023-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00023-3","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"62 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects","authors":"Michelle M Chen, Michael Luu, Wendy L Sacks, Lisa Orloff, Lauren P Wallner, Jon Mallen-St Clair, Susan C Pitt, Allen S Ho, Zachary S Zumsteg","doi":"10.1016/s2213-8587(24)00310-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00310-3","url":null,"abstract":"<h3>Background</h3>In the USA, the incidence of thyroid cancer increased rapidly for several decades, although some studies have suggested that it has now plateaued or even begun to decrease. We aimed to establish whether incidence in the USA has truly decreased or merely plateaued, and to understand some of the underlying factors driving these changes.<h3>Methods</h3>We conducted a retrospective, population-based study using the National Cancer Institute (NCI)'s Surveillance, Epidemiology, and End Results database and the National Center for Health Statistics database. We used incidence data from these registries obtained between 1975 and 2019, including patients with a diagnosis of thyroid cancer according to the third edition ICD for Oncology (site code C73.9) and malignant histology. We used the NCI's Joinpoint Regression Program to estimate trends in the incidence over time and age-period-cohort modelling to identify the factors influencing these trends.<h3>Findings</h3>Our sample included 91 968 patients with thyroid cancer, of whom 23 467 (25·5%) were men and 68 501 (74·5%) were women. The annual incidence of thyroid cancer increased from 5·0 cases per 100 000 people in 1975 to 14·6 cases per 100 000 people in 2009, before plateauing until 2019. The age-period-cohort analysis suggests that the changes in incidence were primarily due to time period effects. Furthermore, the increase in incidence was most prominent among women aged 40–69 years and men aged 50–79 years. Throughout all time periods, incidence increased with each successive birth cohort among both women and men.<h3>Interpretation</h3>The rise and subsequent plateau in the incidence of thyroid cancer in the USA have been primarily driven by time period effects, likely due to changing patterns in diagnostic pressure. Variations in the incidence of thyroid cancer by age, which increased during the time frame of this study, seem to be driven predominantly by overdiagnosis. Although the incidence of thyroid cancer has plateaued, it remains at peak levels, suggesting that overdiagnosis remains a crucial unresolved public health issue. Further work is needed to help limit the current drivers of overdiagnosis and to implement novel solutions aimed at both physicians, patients, and policy makers.<h3>Funding</h3>None.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"13 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in thyroid cancer incidence and overdiagnosis in the USA","authors":"Luigino Dal Maso, Salvatore Vaccarella, Silvia Franceschi","doi":"10.1016/s2213-8587(24)00343-7","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00343-7","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"8 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143192499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 119–33","authors":"","doi":"10.1016/s2213-8587(25)00021-x","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00021-x","url":null,"abstract":"<em>Yang J, Burrello J, Goi J, et al. Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.</em> Lancet Diabetes Endocrinol <em>2025;</em> 13: <em>119–33</em>—In this Article, the spelling of author Ying Song's name was incorrect. In this Article, Jun Yang and Renata Libianto have been added to the affiliation, Department of Endocrinology, Monash Health, Clayton, VIC, Australia. In the panel, the third bullet point under the Clinical outcomes subheading has been changed to a footnote, now cited in the second bullet point under the same subheading. The last sentence of the seventh paragraph of the results section has been corrected to read, “Of the participants with a complete clinical response, 160 (70%) were female, whereas of those with an absent clinical response, 88 (39%) were female.” Appendix 14 of this Article has been corrected. These changes have been made to the online version as of Feb 3, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"39 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143083438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated insulin delivery postpartum: insights from the AiDAPT study extension","authors":"David N O'Neal, Glynis P Ross","doi":"10.1016/s2213-8587(24)00374-7","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00374-7","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"25 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study","authors":"Tara T M Lee, Corinne Collett, Simon Bergford, Sara Hartnell, Eleanor M Scott, Robert S Lindsay, Katharine F Hunt, David R McCance, Rebecca M Reynolds, Malgorzata E Wilinska, Judy Sibayan, Craig Kollman, Roman Hovorka, Helen R Murphy","doi":"10.1016/s2213-8587(24)00340-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00340-1","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Clinical guidelines in the UK and elsewhere do not specifically address hybrid closed loop (HCL) use in the postpartum period when the demands of caring for a newborn are paramount. Our aim was to evaluate the safety and efficacy of HCL use during the first 6 months postpartum compared with standard care.&lt;h3&gt;Methods&lt;/h3&gt;In this prespecified extension to a multicentre, randomised controlled trial, pregnant women with type 1 diabetes at nine UK sites were followed up for 6 months postpartum. Eligible participants (AiDAPT participants recruited after the implementation of the postpartum protocol amendment approval, those still pregnant or within six months of delivery at the time of amendment implementation and still using HCL or continuous glucose monitoring [CGM] therapy) continued their randomly assigned treatment, either standard insulin therapy with CGM or HCL therapy (CamAPS FX system version 0.3.1, CamDiab, Cambridge, UK). Participants were randomised in a 1:1 ratio with stratification by clinical site using randomly permuted block sizes of 2 or 4. The primary outcome was the between-group difference in percentage time in range ([TIR] 3·9–10·0 mmol/L [70–180mg/dL]), measured during the periods of month 0 up to 3, months 3 to 6, and over 6 months postpartum. The study is registered at &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (ISRCTN56898625) and is complete.&lt;h3&gt;Findings&lt;/h3&gt;Of the 124 AiDAPT trial participants, 66 (53%) were ineligible for inclusion in the postpartum extension, and 57 participants consented to continue their treatment per original random allocation. The mean age was 31 years (SD 4), and all participants had early pregnancy HbA&lt;sub&gt;1c&lt;/sub&gt; 59·4 mmol/mol (SD 10·5 [7·6% SD 1·0%]). In the 6 months postpartum, mean time with glucose levels within the target range was higher in the HCL group compared with the standard care group (72% [SD 12%] &lt;em&gt;vs&lt;/em&gt; 54% [17%]), with an adjusted treatment difference of 15% (95% CI 7 to 22). Results for hyperglycaemia (&gt;10·0 mmol/L) and mean CGM glucose also favoured HCL (–14% [95% CI –23% to –6%] and –1·3 mmol/L [–2·3 to –0·3], respectively). Hypoglycaemia rates were low, with no between-group differences (2·4% &lt;em&gt;vs&lt;/em&gt; 2·6%). There were no treatment effect changes depending on postpartum period (0 up to 3 months &lt;em&gt;vs&lt;/em&gt; 3 to 6 months) and no unanticipated safety problems.&lt;h3&gt;Interpretation&lt;/h3&gt;Participants in the HCL group maintained 70% TIR during the first 6 months postpartum, supporting continued use of HCL rather than standard insulin therapy for people with diabetes once they have given birth.&lt;h3&gt;Funding&lt;/h3&gt;National Institute for Health Research, Juvenile Diabetes Research Foundation, and Diabetes Research &amp; Wellness Foundation. CGM devices were provided by","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"117 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions","authors":"Naveed Sattar, Matthew M Y Lee","doi":"10.1016/s2213-8587(24)00363-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00363-2","url":null,"abstract":"The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes. Concurrently, we propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes. However, more evidence is needed to solidify these observations, including, when possible, trials comparing the effects of incretin-based drugs for obesity with calorie-reduced diets on both outcomes and mechanistic pathways. Such evidence has implications for public health and the design of future trials of novel drugs for obesity.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"13 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","authors":"Frederick J Raal, Vimal Mehta, Meral Kayikcioglu, Dirk Blom, Preeti Gupta, Avishay Elis, Traci Turner, Chris Daniels, Jeffrey Vest, Tracy Mitchell, Kate Caldwell, El Mustapha Bahassi, David Kallend, Evan A Stein","doi":"10.1016/s2213-8587(24)00313-9","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00313-9","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Lerodalcibep, a small binding anti-PCSK9 protein (adnectin), showed effective LDL cholesterol reduction in heterozygous familial hypercholesterolaemia. We aimed to assess the safety and efficacy of lerodalcibep and evolocumab in a globally diverse homozygous familial hypercholesterolaemia population.&lt;h3&gt;Methods&lt;/h3&gt;This phase 3, randomised, open-label, crossover, non-inferiority study consisted of two 24-week treatment periods separated by an 8-week washout. The study was conducted in 12 lipid clinics in six countries (India, Israel, Norway, South Africa, Türkiye, and the USA). Patients aged 10 years or older with genetically confirmed homozygous familial hypercholesterolaemia were randomly assigned by computer-generated randomisation scheme performed centrally via interactive response technology to either monthly lerodalcibep 300 mg (1·2 mL subcutaneous injection) or monthly evolocumab 420 mg (subcutaneous 9 min infusion of 3·5 mL) for 24 weeks (period A) followed by an 8-week washout and then crossed over to the alternate therapy for the next 24 weeks (period B). The trial was open label, but all efficacy parameters were masked to patients, study staff, and the sponsor from randomisation. The primary efficacy endpoint was the percent change from baseline (day 1 of period A) in LDL cholesterol concentration to week 24 for period A and B. The intention-to-treat (ITT) population, defined as all randomly assigned patients, was used for the primary analysis. The safety population included all patients who received any study medication. The margin used to establish non-inferiority was 6%. The trial is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (&lt;span&gt;&lt;span&gt;NCT04034485&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;) and EudraCT (2019–003611–62), and has now finished.&lt;h3&gt;Findings&lt;/h3&gt;Patients were enrolled from Nov 11, 2019, to July 2, 2021, and the final study visit took place on Aug 8, 2022. Of 82 patients screened, 66 entered period A (ITT population). The mean age was 28·7 years (SD 15·2); 20 (30%) of 66 were paediatric patients; 36 (55%) of 66 were female and 30 (45%) of 66 were male; and the mean baseline LDL cholesterol was 10·59 mmol/L (SD 4·37). Mean LDL cholesterol reduction by ITT analysis at week 24 was –4·9% (SE 3·5) on lerodalcibep compared with –10·3% (3·5) on evolocumab; the mean difference between treatments was 5·4% (95% CI –0·2 to 11·1), which did not show non-inferiority at the prespecified 6% margin. LDL cholesterol response varied considerably across the patient population but was generally similar in the same patients with both lerodalci","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"3 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143031079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}